Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2015196137) CRYSTALLINE FORMS OF (2R,5S,13AR)-8-HYDROXY-7,9-DIOXO-N-(2,4,6-TRIFLUOROBENZYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1',2':4,5] PYRAZINO [2,1-B] [1,3] OXAZEPINE-10-CARBOXAMIDE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters


CRYSTALLINE FORMS OF 1 METHANOP I C A OX AMIDE CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to and under 35 of Provisional Patent Application Serial filed June 2014 and filed June the disclosures of which are hereby incorporated by reference in their FIELD The present invention relates to novel crystalline forms and of the pharmaceutical and the therapeutic uses BACKGROUND Human immunodeficiency vims infection and related diseases ate a major public health problem Human immunodeficiency virus type 1 encodes three enzymes which are required for viral reverse arid Although drags targeting reverse transcriptase and protease are in wide use and have shown particularly when employed in toxicity and development of resistant strains have limited their usefulness et J Nature A goal of therapy Is to achieve viral suppression in the HIV infected Treatment guidelines published the United States Department of Health and Human Services that achievement of viral suppression requires the use of combination several drags from at least two or drug In decisions regarding the treatment of infected patients are complicated when the patient requires treatment for other medical Because the standard of care requires the use of multiple different drugs to suppress as well as to treat other conditions the patient may be the potential for interaction is a criterion for selection of a drug As there is a need for antirstroviral therapies having a decreased for drug As discussed in application United States Serial filed December 1 entitled COMPOUNDS AND THEIR PHARMACEUTICAL 1 de demonstrates As discussed in application PCX filed December 2013 entitled COMPOUNDS AND THEIR PHARMACEUTICAL i 1 demonstrates 1 has the following It is desired to have physically stable of the compound that are suitable for the therapeutic use and the SUMMARY one aspect the present invention is directed to of 3a 1 j In one the present invention is directed to 1 1 Form L a further fee present invention is directed to Form In a still further the present invention is directed to ide Form In a yet further the present invention is directed to Form In a yet further the invention is directed to In a yet further the present invention directed to 1 Form In a yet further present invention Is directed to 1 a yet further the present is directed to In a certain embodiment fee present Is directed to a acid of 1 In another the present invention is directed to a citric of yet another embodiment the present invention is directed to an oxalic acid crystal of In particular the present is directed to crystalline forms and of In a the present invention is directed to novel forms of sodium having the following structure a still further the present invention is directed to 1 Form I In yet a further the present invention is directed to novel forms of potassium having the following structure In yet another the present invention directed to potassium 1 1 Form In yet another the present invention directed to potassium dn In yet another the present invention is directed to potassium 1 Form a still other the present invention is directed to potassium I 1 in still another the present is directed to of treating or prophyiactically an HIV by administering compound Formulas provided In still another the present invention directed to a compound Formulas provided herein for use in methods of treating or prophyiactically preventing HIV In still another the invention is directed to the use of a compound Formulas provided herein in the manufacture of a medicament for treating or prophyiactically preventing HIV DESCRIPTION OF THE FIGURES Figure It pattern for Form Figure XRPD pattern for 1 Form pattern for Form XRPD for de Form XRPD pattern for sodium 3 5 Figure Actual and calculated XRPD pattern for dio oxalic acid crystal Form Figure DSC for Form DSC for a 1 DSC for sodium Form TGA for Form Figure TGA for 3 ide Form TGA for sodium tritluorobenz 1 Figure DVS for 1 I j Form DVS for Form Figure DVS for sodium Form Figure Calculated Experimental XRPD pattern for DETAILED DESCRIPTION In the following certain specific details set forth in order to provide a thorough of various of the one skilled in the art understand that the invention may be practiced without The description below of several is made with the understanding the present disclosure is to be considered as exemplification of the claimed subject md is not intended to limit the appended claims to the specific embodiments The headings throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any Embodiments illustrated under any heading may be combined with embodiments illustrated under any other Definitions Unless the context requires throughout the present specification and the word and variations such and are to be construed in an inclusive is as but not limited Reference throughout this specification to or means that a particular structure or characteristic described connection with embodiment is included at least one embodiment of the present the appearances of the phrases one or an in various places throughout this specification are not necessarily all referring to the same the particular or characteristics may be combined in any suitable manner in one or more Embodiments that reference throughout tills specification to or includes the and solvate forms of the formulas compounds disclosed the or the phrases or Formulas includes Forms of Formul Form i of Formula Forms of Formula the f citric and oxalic acid as described The invention disclosed herein is also meant to encompass all acceptable compounds of Formulas and being by having one or more atoms replaced by an atom having a different atomic mass or mass Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of and such as and These radiolabeled compounds could he useful to help determine or measure the effectiveness of the by for the site or mode of or binding affinity to pharmacologically important site of Certain compounds of Formulas and for those incorporating a radioactive are useful in drug substrate tissue distribution The radioactive isotopes i and are particularly useful for this purpose in view of their ease of i ncorporation and ready means of Substitution with heavier isotopes such as may afford certain therapeutic advantages resulting from greater metabolic For in vivo life may increase or dosage may heavier Isotopes may he preferred In some Substitution with positron emitting such as and can be useful in Positron Topography studies for examining substrate receptor of Formulas generally be prepared by conventional techniques known to those skilled in the art or by processes to those described in the Examples as set out an appropriate reagent in place of the reagent previously and are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction and into efficacious therapeutic or means that the subsequently described event or circumstances may or may not and the description includes instances where said event or circumstance occurs and instances in which it does For substituted means that the radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no acceptable diluent or includes without limitation any glidant sweetening flavor surfactant wetting dispersing isotonic or which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic A refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to Such a medium includes pharmaceutically acceptable diluents or excipients or effective refers to an amount of a compound according to the which when administered to a patient in need is sufficient to effect treatment for or disorders for which the compounds have Such an would be sufficient to elicit the biological or medical response of a tissue or patient that is sought by a researcher or The amount of a compound according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological acti the composition used for the time of the route of the rate of excretion of the the duration of the the type of or disorder being treated and its drugs used in combination or with the compounds of the and the body general sex and diet of the Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the having regard to their own the state of the this certain the term is intended to mean the administration of a compound or composition according to the present Invention to alleviate or eliminate symptoms of HIV infection to reduce viral load i a The term also encompasses the administration of a compound composition according to the present invention of the individual to the virus but before the appearance of symptoms of the prior to the detection of the virus in the to prevent the appearance of symptoms of the disease to prevent the virus from reaching deteetible levels the and the of a compound or composition according to the present invention to prevent perinatal transmission of from mother to by administration to the mother before giving birth and to the child within the first days of In certain the term as used herein is intended to mean the administration of a compound or composition according to the present invention to alleviate or eliminate symptoms of HIV to reduce viral load in a In certain the term as used herein is further or alternatively intended to mean the administration of a compound or composition according to the present to maintain a reduced viral load in a The term also encompasses the administration of a compound or composition according to the present invention exposure of the individual to the virus but before the appearance of symptoms of the prior to the detection of virus in the to prevent the appearance of symptoms of the disease to prevent the virus from reaching deteetible levels in the and the administration of a or composition according to the present invention to prevent perinatal transmission of HIV from mother to by administration to the mother before giving birth and to the child within the first days of certain the term as used herein is further or alternatively intended to mean the administration of a compound or composition according to the present invention of the individual to the virus as a subsequent or additional therapy to a therapy for maintenance of low viral or means any treatment of a disease or condition that causes the clinical symptoms of disease or condition not to The term also encompasses the administration of compound or composition according to the present inventio of the individual to the virus to prevent the appearance of symptoms of the disease to prevent the virus from reaching levels in the The terms or refer to an such as a a that has been or will be the object of treatment observation or The methods described herein may be useful in human therapy veterinary In subject is a mammal the In some embodiments the subject the is domestic animals dogs and farm goats and laboratory and In one the the is a in need refers to a human who may have or is suspect to have diseases or conditions that would benefit from certain for being treated the compounds disclosed herein according to the present The term as used herein is intended to mean an agent or that is effective to inhibit the formation replication of a virus in a including but not limited to agents that interfere with either host or viral necessary for the formation replication of a virus in a human The term of HIV as used herein is intended to mean an agent capable of reducing or eliminating the ability of HIV to replicate in a host whether in ex vivo or in A refers to a proton shift from one atom of a molecule to another atom of the same The present invention includes tantomers of any said Reference to value or parameter herein includes embodiments that are directed to that value or parameter per For description referring to includes description of the singular forms and include plural references unless the context clearly dictates reference to includes a plurality of such compounds and reference to inclisdes reference to one or more assays and equivalents thereof known to those skilled in or refer to dosage forms and materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical dosage are physically discrete units suitable as unitary dosages for subjects subjects and other each unit containing a quantity of active material calculated to produce the desired therapeutic in with suitable pharmaceutical Crystalline Forms Formula I It desirable to develop a crystalline form of ί that may be useful the synthesis of A form of a earboxamide may an intermediate to the synthesis of 1 1 A polymorphic form or polymorph or may have properties such as and stability at certain conditions that may be suitable for medical or pharmaceutical A crystalline form of 1 may provide the advantage of bioavailability and suitable for use as an active ingredient in a pharmaceutical Variations the crystal structure of a pharmaceutical drug or active ingredient may affect the dissolution rate may affect ease of ability to consistently prepare doses of known and thermal shelf of a pharmaceutical drug product or active Such variations affect the preparation or formulation of pharmaceutical compositions in different dosage or delivery such as solid oral dosage form including tablets and Compared to other forms such as or amorphous crystalline forms may provide desired or suitable particle size dissolution physical and chemical process crystalline forms of may provide advantages such the manufacturing process of an active agent or the stabiiiiy or storability of a drug product form of the compound or an acti ve ingredient having suitable bioavailability stability as an active The use of certain solvents has bee found to produce different polymorphic forms of 1 1 including any one or more of polymorphic Forms and which may exhibit one or mors favorable characteristics described The processes the preparation of the polymorphs described and characterization of these polymorphs are in greater detail The name provided above is named using Ultra and one skilled in the art understands that the compound structure may be named or using other recognized nomenclature systems and By way of the compound may named or identified common systematic or systematic The nomenclature and symbols that are commonly recognized in the art of chemistry including but not limited to Chemical Abstract Service and International Union of Pure and Applied Chemistry the compound structure provided above may also be named or identified as i under IUPAC 1 under CAS Registry Number particular crystalline forms and of are Formula Form I In one provided Is polymorphic Form I of polymorph exhibits an powder diffraction pattens substantially as shown in Polymorphic I may exhibit a differential scanning ealorimetry thermogram substantially as shown Polymorphic Form I may exhibit a thermographic analysis graph substantially as shown in Polymorphic Form I may exhibit dynamic vapour sorption graphs substantially as shown in The as shown when for to an XRPD a DSC or a TGA graph includes a or graph that not necessarily identical to those depicted but that falls within the limits of experimental error or deviations when considered by o e of ordinary skill in the Polymorphic Form I may have a unit cell as determined by crystal crystallography of the following a b c a 90 β and γ 90 In some embodiments of Form at least at least at least at least at least at least at least at least at least at least or all of the following polymorphic Form I has an XRPD pattern substantially as shown in polymorphic Ϊ has a DSC thermogram substantially as shown in polymorphic Form I has a TGA graph substantially as shown In polymorphic Form I has DVS graphs substantially as shown in polymorphic Form Ϊ has a unit as determined by crystal of the following a b c a 90 β and γ polymorphic Form I has an event polymorphic Porta I has a crystal polymorphic Form ί has a space polymorphic Form I has a volume of polymorphic I has a Z value of and polymorphic Form Ϊ has a of In some polymorphic Form I has least at least least or all of the following an XRPD pattern substantially as shown 1 DSC thermogram substantially as shown in DVS graphs substantially as shown in and a unit as determined by crystal of the a b c 90 β and 90 In some polymorphic I has an XRPD displaying at least at least at least at least or at least six of the degree with the greatest intensity as the XRPD pattern substantially as shown in I In certain polymorphic Form I has an XRPD pattern comprising degree degrees at and In one polymorphic Form I has an XRPD pattern comprising degree degrees at and and one or more of the degree degrees at and In one polymorphic Form Ϊ has an XRPD pattern comprising degree flections at and and one of the degree degrees at and one polymorphic Form I has an XRPD pattern comprising degree degrees at and and two of the degree degrees at and In one polymorphic Form I has an XRPD pattern comprising degree 28 degrees at and and three of the degree degrees at and In one polymorphic Form I has XRPD pattern comprising degree 20 degrees at IS In polymorphic Form I has XRPD pattern comprising degree degrees at and In one polymorphic Form I has XRPD pattern comprising any three degree degrees selected from the group consisting of ί and Formula Form II one provided is polymorphic Form II of 1 i wherein the polymorph exhibits an powder diffraction pattern substantially as shown in Polymorphic may have a ceil as determined by crystal crystallography of the following a b c a 90 and γ 90 In some embodiments of polymorphic Form at leas at least at least at least at least at least or all of the following polymorphic Form II has an XRPD pattern substantially as shown in polymorphic Form II has a unit as determined by crystal of the following a b a 90 β and γ 90 polymorphic Form II has a crystal polymorphic Form II has a space polymorphic Form II has a volume of polymorphic Form II has a Z value of and polymorphic Form II has a desisity of In some polymorphic Form II has at least or all of the an XRPD pattern substantially as shown a as determined by crystal of the a b c a 90 β and v 90 In some polymorphic Form II has an X PD pattern displaying at least at least at least at least or at least six of degree the greatest intensity as the XRPD pattern substantially as in certain polymorphic Form has an XRPD pattern comprising degree eflections degrees at and In one polymorphic Form II has an XRPD pattern comprising degree degrees at and and one or of the degree degrees at and In one polymorphic Form II has an XRPD pattern comprising degree degrees at and and one of the degree degrees at and In polymorphic Form II has an XRPD pattern comprising degree degrees at and and two of the degree degrees at and In one polymorphic Form II XRPD pattern comprising degree degrees at and three of the degree degrees at and In one polymorphic Form II has an XRPD pattern comprising degree degrees at and In one polymorphic Form II has an XRPD pattern comprising degree degrees at and In one polymorphic Form II has an XRPD pattern comprising any three degree jections degrees selected the group consisting of and Formula Form IE In one provided is polymorphic Form Hi of rii 1 wherein the polymorph exhibits an powder diffraction pattern substantially as shown Polymorphic Form III may exhibit a differential scanning thermogram substantially as shown in Polymorphic may exhibit a analysis substantially as shown in Form III may exhibit dynamic vapour sorption graphs substantially as shown Polymorphic III may have a as determined by crystal crystallography of the following a b c 90 β and γ 90 In some embodiments of polymorphic Form at least at least at least at least at least at least at least at least at least at least or all of the following polymorphic III has an XRPD pattern substantially as shown in polymorphic III has a DSC thermogram substantially as shown in polymorphic Form ΪΪΙ has a TGA graph as shown in polymorphic Form has DVS graphs substantially as shown in polymorphic Form ΙΙΪ has a unit as determined by crystal of the following a b c a 90 β and 90 polymorphic Form I has an event onset polymorphic Form has a monoelinic crystal polymorphic Form III has a space polymorphic Form has a volume of polymorphic Form III has a 2 value of and polymorphic III has a density of In some III has at least at least at least or of the following an XRPD pattern substantially as shown in a DSC thermogram substantially as shown in DVS graphs substantially as shown in and a unit as determined by crystal of the following dimensions a h c a 90 β 90 In some polymorphic Form III has an XRPD pattern displaying at least at least at least at least fi or at least six of the degree with the greatest intensity as the XRPD pattern substantially as shown in In certain polymorphic Form III has an XRPD pattern comprising degree degrees at and In one polymorphic III has an XRPD pattern degree degrees at and one or more of the degree degrees at and In one polymorphic Form III has an XRPD pattern comprising degree degrees and one of the degree degrees at and In one polymorphic Form III has an XRPD pattern comprising degree degrees at and and two of degree degrees at and Is one embodiment polymorphic Form III has an XRPD pattern comprising degree degrees at and and three of the degree reflections degrees at and In one polymorphic Form HI has an XRPD pattern comprising degree degrees at In one polymorphic Form III has an XRPD pattern comprising degree degrees and In one polymorphic Form has an XRPD pattern comprising any three degree degrees selected from the group consisting of and Formula Form IV in one provided is polymorphic Form of wherein the polymorph exhibits an powder diffraction pattern substantially as in Polymorphic IV may have a unit cell as determined by crystal crystallography of the following a b c a 98 β and γ 90 some embodiments of polymorphic Form at least at least at least at least at least at least or all of the polymorphic Form IV has an XRPD pattern substantially as in polymorphic Form IV has a unit as determined by crystal of the following a b c a 90 β γ 90 Form IV has a crystal IV has a C2 space polymorphic Form IV has a volume of Form IV has a Z value of polymorphic Form IV has a density of some polymorphic Form IV has at least or all of the following an XRPD pattern substantially as shown a unit as determined by crystal of the following a b c 90 p and γ 90 In some polymorphic Form IV has an XRPD pattern displaying at least at least at least at least or at least six the degree with the greatest as XRPD pattern substantially as shown in In certain polymorphic Form IV has an XRPD pattern comprising degree degrees at and In polymorphic IV has an XRPD pattern comprising degree degrees at and and or more of the degree degrees at and In one embodiment polymorphic Form IV has XRPD comprising degree flections degrees at and one of the degree degrees at and In one polymorphic Form IV has an XRPD pattern comprising degree degrees at and and two of the degree degrees and In one polymorphic Form has an XRPD pattern comprising degree degrees at and and three of the degree reflections degrees at and Irs one polymorphic has XRFD pattern comprising degree degrees at and one polymorphic Form has an XRPD pattern comprising degree degrees at arid In one polymorphic Form IV has an XRFD pattern comprising any three degree degrees selected the group consisting of and Formula Form V In one provided is polymorphic Form V of Polymorphic Form V may have a unit cell as determined by crystal crystallography of the following a b c a β and y embodiments of Form at least at least at least at least at least or all of the polymorphic Form V has a unit as determined by crystal of the following a b c a β and γ polymorphic Form V has a triclinic crystal polymorphic V has a space polymorphic V has a volume of polymorphic Form V has a Z value of a d polymorphic Fonts V has a density of Mg In some polymorphic Form V has following a nnit as determined by crystal of the following a b c and γ Formula Form VI In one provided is polymorphic Form VI of a I Polymorphic Form VI may have a as determined by crystal crystallography of the following a b c 90 β and γ 90 some of at least at least at least at least at least or all of the following polymorphic Form VI has a as determined by crystal crystallography of the following a b c 90 β and γ 90 polymorphic Form VI has a crystal polymorphic Form V has a space polymorphic Form VI has a volume of polymorphic Form V has a Z value of and polymorphic Form V has a density of In some polymorphic Form VI has the following a as determined by crystal of the following a b a 90 β and γ Formula Form VII one provided is polymorphic Form VII of 1 Polymorphic Form VII may have a unit as determined by crystal crystallography of the following b a 90 β and γ 90 In some of polymorphic Form at least at least at least at least at least or all of the following polymorphic has unit as determined by crystal crystallography of the following a b c 90 β and 90 polymorphic Form VII has a monoclinic crystal polymorphic Form VII has a space polymorphic Form has a votome of polymorphic Form has a Z value of and polymorphic Form VII has a density of some polymorphic Form VI has the following a unit as by crystal crystallography of the following a b c a 90 β and γ 90 Formula Form VIII In one provided is polymorphic Form VIII of Polymorphic Form VIII may have a unit cell as determined by crystal crystallography of the following a b e a 90 β γ 90 In some embodiments of polymorphic at least at least at least at least at least or all of the following polymorphic a unit as determined by crystal of the following a b c 90 β and γ 90 polymorphic Form VIII has a crystal polymorphic Form VIII has a C2 space polymorphic Form VIII has a volume of polymorphic Form has a Z value of and polymorphic Form VIII has a density of Mg some polymorphic Form VET has the following a unit as determined by crystal of the following a b c a 90 β γ 90 Formula 11 It Is desirable to develop a crystalline form of sodium that may be useful in the synthesis of sodium A form of sodium 1 1 oiate may be intermediate to the synthesis of sodium A form of sodium may be the product in the synthesis of 1 1 A polymorphic form or polymorph or eocrystal may have properties such as bioavailability and stability at certain conditions that may be suitable for medical or pharmaceutical A crystalline form of sodium may provide the advantage of bioavailability and suitable for use as active in a pharmaceutical In certain a crystalline forro sodium i provides an advantage of improved bioavailability stability Variations in crystal structure of a pharmaceutical drug substance or active ingredient may affect the dissolution rate may affect ί ity ease of ability to consistently prepare doses of known and stability thermal shelf of a pharmaceutical drug product or active Such variations may affect the preparation or formulation of pharmaceutical compositions different dosage or such as solid dosage form including tablets and Compared to other forms such as noncrystalline or amorphous crystalline may provide desired or suitable h particle size dissolution physical and chemical process crystalline forms of sodium advantages such improving the process of an active agent or the stability or of a drug product form of the active having suitable stability as an active The use of certain solvents has beers found to produce different polymorphic forms of sodium including polymorphic Form which may exhibit one or more favorable characteristics described Form I of provides an advantage of improved bioavailability stability The processes for the preparation of polymorphs described herein and characterization of these polymorphs are described in greater detail The compound name provided above is named ChemBioDra Ultra and one skilled in the art understands that the compound structure may be named or identified using other commonly recognized nomenclature systems and By way of the compound may be named or identified with common systematic or systematic The nomenclature systems and symbols that are commonly recognized in the art of chemistry including but not limited to Chemical Abstract Service and International Union of Pure and Applied Chemistry Accordingly the compound structure provided above may be named or identified as sodium under particular crystalline forms of sodium a are Formula II Form I In a certain embodiment novel forms of having the following structure are a further crystalline forms of sodium are a certain embodiment sodium Form is In one provided is polymorphic Form I of sodium wherein the polymorph exhibits an powder diffraction pattern substantially as shown in 5 Polymorphic sodium Form I may exhibit a differential scanning thermogram substantially as shown Polymorphic sodium Form may exhibit a thermographic analysis graph substantially as shown in Polymorphic sodium Form I may exhibit dynamic vapour sorption graphs substantially as shown in The term as shown when for to an XRPD DSC or a TGA graph includes a thermogram or graph that is not necessarily identical to those but that falls within the of experimental error or deviations when considered by one of ordinary skill in the sodium Form Ϊ may have a unit cell as determined by crystal of the following a b c 90 β 90 and γ 90 some embodiments of polymorphic sodium Form at least at least at least at least at least at least at least at least at least all of the following polymorphic Form I has an XRPD pattern substantially as in 5 polymorphic Form I has a DSC thermogram substantially as in polymorphic sodium Form I has a TGA graph substantially as shown in polymorphic sodium Form I has DVS graphs substantially as shown in polymorphic sodium Form I has a unit cell as determined by crystal of the following a b c 90 β 90 and γ 90 polymorphic sodium Form ί has an crystal polymorphic sodium Form I has a P212I21 space polymorphic sodium Form I has a volume of Form I has a Z value of polymorphic Form I has a density of some polymorphic sodium I has at least at least at least at least or all of the following an XRPD pattern substantially as shown in 5 a DSC thermogram substantially as shown in TGA graphs substantially as shown in DVS graphs substantially as shown in and a unit as determined by crystal of the following dimensions a b c 90 β 90 and y 90 In some polymorphic sodium Form I has an XRPD pattern displaying at least at least at least at least or at least six of fee degree with the greatest intensity as the XRPD pattern substantially as shown in 1 In polymorphic sodium Form I has an XRPD pattern comprising degree degrees at In embodiment polymorphic sodium Form I has an XRPD pattern comprising degree degrees at and and one or more of the degree degrees at and n one polymorphic sodium Form I has an XRPD pattern comprising degree degrees at and and one of the degree degrees at and In polymorphic sodium Form I has an pattern comprising degrees at and and two of the degree degrees at and one polymorphic sodium I has an XRPD pattern comprising degree degrees at and and three of the degree degrees at and In one polymorphic Form I has an XRPD pattern comprising degree degrees at In one polymorphic sodium Form I has an XRPD pattern comprising degree refleciions degrees at and in one polymorphic sodium Form I has an XRPD pattern comprising any three degree degrees selected from the group consisting of and III It is desirable to develop a crystalline form of potassium that may be useful in the synthesis of potassium A form of a potassium may be an intermediate to the synthesis of potassium A form or polymorph or cocrystal may have properties such as bioavailability and stability at certain conditions that may be suitable for medical or pharmaceutical A of potassium may provide the advantage of bioavailability and suitable for use as an active in a pharmaceutical Variations in the crystal structure of a pharmaceutical drug substance or active ingredient may affect the dissolution rate may affect ease of ability to consistently prepare doses of known and stability thermal shelf of a pharmaceutical product or active ingredient Such variations may affect the preparation or formulation of pharmaceutical compositions in different dosage or delivery sack as oral dosage form including tablets and Compared to other forms such as or amorphous crystalline forms provide desired or suitable particle size dissolution and chemical process crystalline forms of potassium 1 n 1 may provide advantages such improving the manufacturing process of an active agent or the stability or storability of a drug product form of the compound or an active having suitable bioavailability stability as an active The use of certain solvents has been found to produce different polymorphic forms of potassium including any one or more of polymorphic Forms and III which may one or more favorable characteristics described The processes for the preparation of the polymorphs described and characterization of these polymorphs are described in greater detail The compound name provided above is named using Ultra and one skilled in the art understands that the compound structure may be named or identified using other recognized nomenclature systems and way of the compound may be named or with common systematic or systematic T he nomenclature systems symbols that are commonly recognized in the art of chemistry but not limited to Chemical Abstract Service Union of Pure and Applied Chemistry the compound structure provided above may be named or identified as 1 under particular crystalline forms and of potassium are yet a further novel forms of potassium having the ibiiowing structure are In yet another potassium Form I is In yet another potassium 3a Form II is In yet potassium Form III is In a still other potassium 1 Is Formula Form I In provided is polymorphic Form I of potassium J Polymorphic potassium Form I may have a unit cell as determined by crystal ray crystallography of the following a b a 90 β 90 and γ 90 In some of polymorphic potassium Form at least at least at least at least least or of the followkg polymorphic Form I has a unit as determined by crystal of the following a b c a 90 β 90 and γ 90 potassium I has an orthorhombic crystal polymorphic potassium Form I has a P 21 21 2 space polymorphic potassium Form I has a volume of polymorphic potassium Form I has a Z value of and potassium Form I has a density of Mg In some polymorphic potassium Form 1 has the following a unit as determined by crystal of the following dimensions a b c a 90 β 90 and γ 90 Formula Form In one provided is polymorphic Form II of potassium 3a 1 1 Polymorphic potassium Form II may have a unit as determined by crystal ray crystallography of the following a b c 90 β 90 and γ 90 some embodiments of potassium Form at least at least at least at least at least or all of the following polymorphic potassium Form II has a unit as determined by crystal of the following a b c a 90 β 90 and γ 90 polymorphic potassium Form has an orthorhombic crystal polymorphic potassiwm Form ΪΙ has a P 21 2 space polymorphic potassium Form II has a volume of polymorphic potassiwm Form II has Z value of and polymorphic potassium Form Π has a density of In some polymorphic potassium Form II has following a unit as by crystal of the following dimensions a b 103029 c a 90 β 90 and γ 90 Formula Form In one provided is polymorphic Form III of potassium potassium Form III may have a unit as determined by crystal ra crystallography of the following a c a β and In some embodiments of polymorphic potassium Form at least at least at least at least at least or of the following polymorphic potassium Form ΙΠ has unit as determined by crystal of the following a c β and γ potassium has a triclmic crystal polymorphic potassium Form has a space polymorphic potassium Form HI has a volume of polymorphic potassium Form has a Z value of and potassium has a density of In some potassium Form has the following a unit as determined by crystal of the following dimensions a b c a β and γ Formula Citric Acid In a citric acid of rifluoroben is In one provided is Formula I citric acid of x 52 Formula Ϊ citric may have a unit as determined by crystal ray crystallography of the following a b c a β and γ som embodiments of I citric acid at least least at least at least at least or all of following Formula I acid stal has a unit as determined by crystal of the a b c β γ Formula citric acid has a crystal Formula I citric acid has a space Formula I citric acid has a volume of Formula citric has Z value of and Formula I citric acid has a density of In some Formula ϊ citric acid has all of the following a unit as determined by crystal of the following dimensions a b c p γ Formula 1 Fumaric Acid a a fumaric acid of 7 is In one provided is I fumaric acid of 1 1 Formula I acid may have a unit as determined by crystal ray crystallography of the following b c 90 β and γ 90 In some embodiments of Formula I fumaric acid at least at least at least at least or ail of the following Formula I fumark acid has a unit as determsned by crystal of the following a b c 90 β and 90 Formula fumaric has a monoclmic crystal Formula I fumaric has a C2 space Formula I fumaric acid has a volume of Formula i fumaric acid has a Z value of and Formula Ϊ fumaric acid has a density of Mg In some Formula I fumark acid has all of the following a unit as determined by crystal of the following dimensions a e a 90 β γ 90 Formula 1 Oxalic Acid In yet another embodiment a oxalic of 1 is embodiment provided is I oxalic acid of 1 1 Formula I oxalic may have a unit ceil as by crystal ray crystallography of the a b c a 90 β 90 of Formula i oxalic acid at least at least at least at least at least or of the oxalic acid has a unit as by crystal of the following a b c 90 β y 90 Formula Ϊ oxalic acid has a rnonoclink crystal Formula I oxalic acid bas a space Formula oxalic acid has a volume of I oxalic acid has a Z value of and Formula Ϊ oxalic acid has a density of g Irs some Formula I oxalic acid has the following unit as determined by crystal of the following dimensions a b c 90 β and γ 90 In certain Formula I oxalic acid has an XRPD pattern comprising degree degrees at and In one Formula I oxalic acid has an XRPD pattern comprising degree degrees at and and one or more of the degree reflections degrees at and In one Formula I oxalic acid has an XRPD pattern comprising degree degrees at and one of the degree degrees and one embodiments Formula I oxalic acid has an XRPD pattern comprising degree degrees at and two of the reflections degrees at and In one embodiment I oxalic has an XRPD pattern comprising degree degrees at and and three of the degree degrees at and In one Formula I oxalic acid an XRPD pattern comprising degree degrees at and In one 1 oxalic acid has an XRPD pattern comprising degree reflections degrees at and In one polymorphic Formula 1 has an XRPD pattern comprising any three degree degrees selected from the group consisting of and Compositions For the purposes of in certain the compounds described herein are administered as a raw chemical or are formulated as pharmaceutical Pharmaceutical compositions of the present Invention comprise a compound of Formulas or including forms and and a pharmaceutically acceptable diluent or The of Formulas or is present in the composition in amount which is effective to treat a disease or condition of The activity of compounds of Formulas and can be determined by one skilled in the for as described in Serial filed December 2013 entitled COMPOUNDS AND THEIR PHARMACEUTICAL The activity of of and can also he determined by one skilled on the for as in PCX Serial US2G filed December 2013 COMPOUNDS AND THEIR PHARMACEUTICAL Appropriate concentrations and dosages can be determined by one skilled in the In certain a compound of Form ulas is present the pharmaceutical composition in an amount from about 25 mg to about 500 In certain a compound of Formulas is present in the pharmaceutical composition in an amount of about to about 300 In certain a compound of Formulas is present the pharmaceutical composition in an amoun t of about 5 mg to about 00 In certain a of Formulas is present in the pharmaceutical composition in an of about 25 mg to about 100 In certain a of Formulas is present In the pharmaceutical composition an amount of about 50 mg to about In certain a compound of Formula present in the pharmaceutical composition in an amount of about 5 25 50 100 200 400 mg or about 500 Formula I Provided are also compositions comprising at least at least at least at least at least at least at least or all of polymorphs any one or more of Formula Ϊ polymorphic Forms and as described a particular a composition comprising one of Formula I polymorphic Forms and VIII described herein is In a particular a composition comprising two of Formula polymorphic Forms and VIII described herein is In a particular a composition comprising three of Formula polymorphic Forms L and VIII described is In a particular embodiment a composition comprising four of Formula 1 polymorphic Forms XL and VIII described herein is In a particular a composition comprising five of Formula I Forms V and VIII described herein is In a particular a composition comprising six of Formula I polymorphic Forms and VIII described herein is In a particular a comprising seven of Formula I polymorphic Forms and VIII described herein is In a particular a composition comprising eight of Formula I polymorphic Forms and VIII described herein is In other the compositions described herein may comprise substantially polymorphic or may be substantially free of other polymorphs some the composition comprises a polymorphic form of i In certain embodiments are provided compositions comprising a polymorphic form as described wherein the 1 octa 1 within the composition is substantially pure substantially pure Form Form Form Form Form Form VI or Form VII or Form I particular of compositions comprising a polymorphic form of at least about at least about at least about at least about at least about at least about at least about at least about at least about at least about or at least about present in the composition is one of the polymorphic forms disclosed In certain the composition includes at least about at least about at least about at least about at least about at least about at least about at least about at least at least about or at least about of one of the polymorphic forms of in other embodiments of compositions comprising a polymorphic form disclosed less than about less about less than about less than about less than about less than about than about less than about less than about or less than about of 1 i present in the composition are other of 1 yet other embodiments of compositions comprising the polymorphic forms disclosed impurities make up less than about less than about less than about than about or less than about of the total mass relative to the mass of the polymorphic forms for include from synthesizing 3a other polymorphic amorphous and certain impurities include from the process of synthesizing In certain include contaminants from the process of certain impurities include degradation products of In certain impurities include other polymorphic forms of 1 certain impurities include water or In certain embodiments of compositions comprising a polymorphic form disclosed impurities are selected from the group consisting of from synthesizing degradation other polymorphic solvents and combinations In yet other the composition comprising a polymorphic form disclosed herein has than about less man about less than about less than about or less than about by weight of amorphous or d i Formula 11 Provided are also compositions comprising at least one polymorph any one or more of Formula II polymorphic Forms as described In a particular a composition comprising Formula ΙΪ polymorphic Form described herein is other compositions described herein may comprise substantially pure polymorphic may be substantially free of other polymorphs In some the composition comprises a polymorphic form of sodium certain embodiments are provided comprising a polymorphic form as described wherein the sodium within the composition is substantially pure pure Form In particular embodiments of compositions comprising a polymorphic of sodium at least about at least about at least about at least about at least about at least about at least about at least about at least about at least about or at least about J J present in the composition is Formula disclosed In certain the composition includes at least about at least about at least about at least about at least about at least about at least about at least about at least about at about or at least about of Form I of sodium In other embodiments of compositions comprising a polymorphic form disclosed less than about less than about less than about less than about less than about less about less than about less than about less than about or less than about of sodium present In the composition are other polymorphs of sodium In yet other embodiments of compositions comprising the polymorphic forms disclosed impurities make less than about less than about less than about less than about or less than about of the total mass relative to the mass of the polymorphic forms Impurities for include from synthesizing sodium id degradation other polymorphic amorphous and impurities include from the process of synthesizing sodium In certain impurities include contaminants from the process of synthesizing sodium In certain impurities include degradation products of sodium 58 n certain impurities include other forms of sodium certain impurities include water or In certain embodiments of compositions comprising a polymorphic form disclosed impurities are selected from the group consisting of products from synthesizing sodium degradation other polymorphic solvents and combinations In other the composition comprising Formula I disclosed herein has less than about iess than about less than about less than about or than about by weight of amorphous or sodium some the term or with respect to a particular polymorphic form of a compound means that the comprising the polymorphic form contains less than less than less than less than less than less than less than less than less than less than less than less than than less than or less than by weight of other including other polymorphic forms In certain or of refers to a substance free of other other polymorphic forms Impurities for include or left over reagents from chemical degradation other polymorphic and sol Formula III Provided are also compositions comprising at least or of polymorphs any one or more of Formula III polymorphic Forms and as described In a particular a composition comprising one of Formula III polymorphic Forms and III described herein is In a particular a composition comprising two of Formula ΙΙΪΙ polymorphic Forms and III described herein is other the compositions described herein may comprise substantially pure polymorphic or may be substantially free of other polymorphs In some the composition comprises a polymorphic form of potassium In certain embodiments are provided compositions comprising a polymorphic form as described wherein the potassium within the composition is substantially pure substantially pure Form In particular embodiments of compositions comprising a form of potassium at least about at least about at least about at least about at least about at least about at least about at least about at least about at least about or at least about of potassium irifiuoroben present in composition is of the polymorphic forms di sclosed I certain the composition includes at at least about at least about at least about at least about at least about at least about at least about at least about at least about or at about of one of the polymorphic forms potassium In other e bodiments of compositions comprising a polymorphic form disclosed less than about less about less than about less than about less than about less than about less than about less than about less than about or less than about of potassium r ethanop l present in the composition are other polymorphs of potassium yet other embodiments of compositions comprising the forms disclosed impurities make up less than about less than about less than about less than about or less than about of the total mass relative to the mass of the polymorphic forms impurities for include from potassium degradation other polymorphic and sol In certain impurities include from the process of synthesizing potassium 13 certain impurities include contaminants from the of synthesizing potassium In certain impurities include degradation products of potassium 1 In certain impurities include other polymorphic forms of potassium i 3a certain include water or solve In certain embodiments of compositions comprising a polymorphic form disclosed impurities are selected the group consisting of products from synthesizing potassium degradation other polymorphic solvents and combinations In yet other the composition comprising a polymorphic form disclosed herein has less than less than about less than about less than about or less than about weight of amorphous or potassium Provided are also compositions comprising at least at least at least at least at least at least at least at least at least at least or ail of polymorphs any one or more of Formula I polymorphic Forms VI and Formula II polymorphic Form polymorphic Forms as described In a particular embodiment composition comprising of Formula I Forms and Formula II polymorphic Form Formula III polymorphic Forms and III described herein is In a particular composition comprising two of Formula I polymorphic Forms and Formula II polymorphic Form III polymorphic Forms and III described herein is In a particular a composition comprising three of Formula I polymorphic Forms and Formula II polymorphic Form Formula II polymorphic Forms and III described herein is In a particular a composition comprising four of Formal Formula 1 polymorphic Forms and Formula II polymorphic Form Formula III Forms and described herein is In a particular a composition comprising five of I polymorphic Forms and Formula II polymorphic Form Formula III polymorphic Forms and III described herein In a a composition comprising six of Formula I Forms and Formula II polymorphic Form Formula III polymorphic Forms and III described herein is In a particular a composition comprising seven of Formula I polymorphic Forms and Formula Form Formula III polymorphic Forms HI described herein is In a particular a composition comprising eight of Formula I polymorphic Forms Formula II polymorphic Form Formula III polymorphic and III described herein is In a particular embodiment a composition comprising nine of Formula I polymorphic and Formula II polymorphic Form Formula polymorphic Forms III described herein In a particular a composition comprising ten of Formula I polymorphic Forms and Formula II polymorphic Form Formula III polymorphic Forms and HI described herein is In a particular a composition comprising eleven of Formula I polymorphic Forms and Formula II polymorphic Form Formula III polymorphic Forms and III described herein is other the compositions described herein may comprise substantially pure polymorphic or may be of other polymorphs In some the or with respect to particular polymorphic form of a compound means that the composition comprising the polymorphic form contains less than less than less than less than less than less than less than less than less than less than less than less than less than less than or less than by weight of other including other polymorphic forms In certain or free refers to a substance free of other including other polymorphic forms Impurities for or left over reagents from chemical degradation other polymorphic and Administration of the compounds of the invention in pure form or in an appropriate pharmaceutical can be carried out via any of the accepted modes of administration of agents for serving similar The pharmaceutical compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically diluent or and may be formulated preparations in liquid or gaseous such as and The pharmaceutical compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable diluent or and may be formulated into preparations in liquid or gaseous such as solid dispersions and solid Typical routes of administering such pharmaceutical without and In the pharmaceutical compositions is prepared for oral In a specific the pharmaceutical composition is a Pharmaceutical compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the compositio to a Compositions that will be administered to a subject or patient take the form of or more dosage where for a tablet may be a single dosage and a container of a compound of the invention in aerosol may hold a plurality of dosage Actual methods of preparing such dosage forms are or will be apparen to those skilled in this for see The Science and Practice of 20th Edition College of Pharmacy and The composition to be administered in any contain a therapeutically effective amount a compound of the invention for treatment of a disease or condition of in accordance with the teachings of this The pharmaceutical compositions of the invention be prepared by methodology well in the pharmaceutical For a pharmaceutical composition intended to be administered by injection be prepared by combining a compound of the invention with distilled water so as to form a A surfactant may be added to facilitate of a homogeneous solution or Surfactants are compounds that interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous For a solid pharmaceutical composition intended for oral administration be prepared by mixing a compound of the invention with at least one suitable pharmaceutical excipient to form a solid eformulation which then may be readily subdivided into equally effective unit dosage forms such as pills and Accordingly in embodiment a pharmaceutical composition is which a compound of Formula or a pharmaceutical The compounds of the are in a therapeutically effecti ve amount which will vary depending upon a variety of factors including the activity of the specific compound the metabolic stability and length of action of the the body general and diet of the the mode and time of the rate of the drug the severity of the particular disorder or and the subject some the compounds of the ention can administered alone or is combination with other antiviral agents once or twice daily for as long as the patient is latently or to prevent infection for multiple or Combination Therapy one a method for treating or preventing an HIV infection in a human having or at risk of having the infection is comprising administering to the human a therapeutically effective amount of a compound disclosed herein combination with a therapeutically effective amount of one or more one or or one to additional therapeutic In one a method for treating an HIV infection in a human having or at risk of having the infection is comprising administering to the human a therapeutically effective amount of a compound disclosed herein in combination with a therapeutically effective amount of one or more one or or one to additional therapeutic In one a method for treating an HIV infection in a human having or at of having the infection is comprising administering to the human a effective amount of a compound or composition disclosed herei In combination with a therapeutically effective amount of one or more one or or one to additional therapeutic In certain the present invention provides a method for treating an HI comprising administering to a patient in need thereof a therapeutically effective amount of a compound or composition disclosed herein in combination with a therapeutically effective of one or more additional therapeutic agents which are suitable for treating an HIV One embodiment provides a disclosed herein in combination with one or more one or or one to additional therapeutic agents for use a method for treating or an HIV infection in a human having or at risk of having the One embodiment provides a compound disclosed herein in combination one or more one or one to additional therapeutic agents for use in a method for treating an HIV in a human having or at risk of having the One provides a compound disclosed herein for in a method for treating or preventing a HIV infection a human having or at risk of having the wherein the compound is administered in combination with or more one or or one to additional One embodiment provides a compound disclosed herein for use in a for treating an HIV infection in a human having or at risk of having the wherein the compound is administered in combination with one or more one or or to additional therapeutic certain the present invention provides a compound disclosed herein in combination with one or more additional therapeutic agents which are suitable for treating an HIV for nse in a method for treating an HIV certain the present invention provides a compound disclosed herein for use in a method for treating an HIV wherein the compound is administered in combinatio with one or more additional therapeutic agents which are suitable for treating an HIV One embodiment provides the use of a compound disclosed herein in combination with one or more one or or one to additional therapeutic agents in the manufacture of a medicament for treating or preventing an HIV infection in a having or at risk of having the One provides the use of a compound disclosed herein in combination with one or more one or or one to additional therapeutic agents in the manufacture of a medicament for treating an HIV infection in a human having or at risk of having the One embodiment provides the use of a compound disclosed herein in the manufacture of a medicament for treating or preventing an HIV infection in a human having or at risk of having the the compound administered in combination with one or more one or or one to additional therapeutic One provides the use of a disclosed herein in the manufacture of a for an HIV infection human having or at risk of having the wherein the compound is administered in combination with one or more one or or one to additional therapeutic certain the present invention provides the use of a disclosed herein in combination with one or more additional therapeutic agents which are suitable for treating in treating an certain the present invention provides the use of a compound disclosed herein thereof for treating an HIV wherein the compound is administered with one or more additional therapeutic agents which are suitable for treating an HIV A compound as disclosed herein my compound of Formulas may be combined with one or more additional therapeutic agents in any dosage amount of the compound of Formulas 50 to of one pharmaceutical compositions comprising a compound disclosed herein in combination with one or more one or or one to additional therapeutic and a acceptable diluent or are In one combination pharmaceutical agents comprising a compound disclosed herein in combination with or more one or or one to additional therapeutic agents are In one kits comprising a compound disclosed herein in combination with one or more one or or one to additional therapeutic agents are In the above the additional therapeutic agent may be an For some the additional therapeutic agent is selected from the group consisting of HIV protease HIV inhibitors of HIV nucleoside or nucleotide inhibitors of reverse HIV HIV site integrase entry inhibitors inhibitors fusion and CD4 attachment CXCR4 G6PD that target the HIV capsid polymerization inhibitors or capsid disrupting compounds such as those disclosed Irs WO US of and WO pharmacokinetic and other drags for treating and combinations In other the therapeutic agent may be an For In some the additional therapeutic agent is selected from the group consisting of HIV protease HIV or inhibitors of reverse HIV nucleoside or nucleotide inhibitors of reverse HIV HIV site integrase HIV entry inhibitors CCR5 inhibitors fusion and CD4 attachment G6PD and HIV HIV maturation latency reversing agents histone proteasoroe protein C and BRD4 compounds that target the HIV capsid capsid polymerization inhibitors or capsid disrupting HIV p7 HIV p24 capsid protein pharmacokinetic therapies like receptors HIV antibodies and therapeutic proteins TandAbs Fab including those targeting or combination drags for HIV matrix protein A disulfide Complement C5a receptor DNA HIV vif gene Vif viral factor protein Nef Hck tyrosine kinase mixed lineage splicing Rev protein Nucleoprotein Splicing factor COMM domain containing protein 1 HIV H Dendritic grabbing 1 HIV GAG protein HIV POL protein Complement Factor H kinase dependent kinase inhibitors Proprotein corsvertase PC9 ATP dependent RNA helicase reverse transcriptase priming complex HIV gene PI3 compounds such as those disclosed WO US of WO WO WO WO 100323 and WO and WO and other drugs for treating combinations In certain the additional therapeutic is selected from group consisting of HIV protease H1Y or of reverse HIV nucleoside or nucleotide inhibitors of reverse integrase HIV site integrase pharmacokinetic and combinations certain embodiments a compound of Formulas is formulated as a which may optionally contain one or more other compounds useful for treating certain the tablet can contain another active ingredient for such as HIV protease HIV or of reverse HIV nucleoside or nucleotide inhibitors of reverse HIV integrase HIV site integrase pharmacokinetic and combinations In certain the tablet can contain one or more active ingredients for treating such as HIV nucleoside or nucleotide Inhibitors of reverse In certain such tablets are suitable for once daily In further the additional therapeutic agent is selected from one or more HIV protease inhibitors selected from group consisting of mo enavir and AG HIV or inhibitors of reverse transcriptase selected from the group consisting of 355 nucleoside or nucleotide inhibitors of reverse transcriptase selected from the group consisting of abacavir aprieitlbine KIM fosalvudine tidoxil HDP tenofovir tenofovir tenofovir alafenamide tenofovir alafenamide adefovir and inhibitors selected from the group consisting of derivatives chicoric derivatives of chicoric derivatives of derivatives of aarintricarboxylic caffeic acid derivatives of caffeie acid phenethyi derivatives of derivatives of and raitegra and or integrase not limited compounds disclosed in WO WO 2 WO WO WO WO each of which is incorporated by references in its entirety inhibitors selected from the group consisting of and the the entry Inhibitor the inhibitor the G6PD and inhibitor CCRS Inhibitors selected from the group consisting of and CD4 attachment inhibitors selected from the group consisting of and enhancers selected from the group consisting of cobicistai and and other drugs for treating HIV selected from the group consisting of REP AMZ CYT BAY PBS ALG and and combinations certain additional agent is selected from one or more Combination drugs selected from the group consisting of disoproxil or disoproxil fumarate disoproxil fumarate abacavir sulfate nevirapine sulfate atazanavir tenofovir alafenamide emtricitabine tenofovir alafenamide tenofovir tenofovir alafenamide hemifismarate emtricitabine tenofovir alafenamide emtricitabine darunavir tenofovir alafenamide emtricitabine cobicistai atazanavir sulfate abacavir sulfate disoproxil fumarate ienofovir disoproxil doravirine ienofovir tenofovir lamivudine lamivudine tenofovir disoproxil HIV protease selected the group consisting of indinavir nelfinavir saquinavir and T HIV or inhibitors of reverse transcriptase selected from the group consisting of and HIV nucleoside or nucleotide inhibitors of reverse transcriptase selected from the group consisting of and EC zido abacavir amdoxovir tenofovir ienofovir disoproxil tenofovir disoproxil tenofovir tenofovir alafenamide tenofovir alafenamide adefovir and HIV integrase inhibitors selected from the group of derivatives of derivatives of chicoric 3 derivatives of derivatives of aurintricarboxyiic caffeic acid derivatives of caffeic acid derivatives of derivatives of and HIV or integrase inhibitors selected from the group consisting and HIV inhibitors selected from the group consisting of sifuvirtide and HIV entry inhibitors selected the group consisting of HIV g inhibitors selected from the group consisting of and inhibitors selected from the group consisting of Adaptavir O 1 nifeviroc and CD4 attachment inhibitors selected from the group consisting of inhibitors selected from the group consisting of vMIP and enhancers selected from the group consisting of and therapies selected from the group consisting of proleukin if interferon interferon interferon pegylated interferon interferon mofetil and its ester derivative receptors modulators tirl2 and and HIV vaccines selected from the group consisting of peptide recombinant subunit protein live vector DNA particle vaccines peptide vaccine ALVAC HIV monomelic subtype C vaccine Contre DNA recombinant V Tat Oyi rVSVIN gag HIV AX NY V D rAAV l i 1 C 001 and HIV bispecific antibodies therapeutic proteins as TandAbs Fab including and those targeting HIV or gp41 selected the group consisting of 1 17 and latency reversing agents selected from the group consisting of inhibitor such as inhibitors such as protein kinase C activators such as B and GS BRD4 and amphotericin nucleocapsid p7 inhibitors selected from the group cons sting of carbonamide HIV inhibitors selected from the group of and inhibitors selected the group of rigosertib GS ZST and the compounds in WO WO WO WO US of WO WO WO WO WO WO 5728 Scie and WO and other drugs for treating HIV selected the group consisting of M REP HI MazF gene therapy and and combinations In certain a compound disclosed herein Is combined with four or more additional therapeutic certain a compound disclosed herein Is combined with two therapeutic In other a compound disclosed herein Is combined with three additional therapeutic In further a compound disclosed herein is combined with four additional therapeutic The three four or more additional therapeutic agents can be different therapeutic agents from the same class of therapeutic or they can be selected from different classes of therapeutic a specific a compound disclosed herein is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV inhibitor of reverse another specific a compound disclosed herein is combined with an HIV nucleoside or nucleotide inhibitor of reverse and an HIV protease inhibiting In a further a compound disclosed herein is with an HIV nucleoside or nucleotide inhibitor of reverse an HIV inhibitor of reverse and an HIV protease inhibiting In an additional a compound disclosed herein is combined with an HIV nucleoside or nucleotide inhibitor of reverse an inhibitor of reverse and a pharmacokinetic In another a compound disclosed herein is combined two HIV nucleoside or nucleotide inhibitors of reverse In certain a compound disclosed is combined with four or more additional therapeutic In certain a compound dssciosed herein is combined with additional therapeutic In certain a compound disclosed herein is combined with two therapeutic In other compound disclosed herein is combined with three additional therapeutic In further a disclosed herein is combined with four additional therapeutic The or more additional therapeutic agents can be different therapeutic selected from the same class of therapeutic they can be selected from d classes of therapeutic In a specific a compound disclosed herein is combined with an HIV nucleoside nucleotide inhibitor of reverse transcriptase and an inhibitor of reverse another specific a compound disclosed herein is combined with an HIV nucleoside or nucleotide inhibitor of reverse and an HIV protease a further a compound disclosed herein is combined with an HIV nucleoside or nucleotide inhibitor of reverse an HIV inhibitor of reverse ami an HIV protease inhibiting In an additional a compound disclosed herein is combined with an HIV nucleoside or nucleotide inhibitor of reverse an HIV inhibitor of reverse and a pharmacokinetic In a compound disclosed herein is combined with at least one HIV nucleoside inhibitor of reverse an integrase and a pharmacokinetic In another a compound disclosed herein is with two nucleoside or nucleotide inhibitors of In certain a compound disclosed herein is combined with at least one HIV nucleoside inhibitor of reverse an integrase and a pharmacokinetic In a particular a compound disclosed herein is combined with abacavir tenofovir tenofovir or tenofovir alafenamide In a particular a compound disclosed herein is combined with tenofovir disoproxil tenofovir or tenofovir alafenamide In a particular embodiment a compound disclosed herein is combined with a first additional therapeutic agent selected the group consisting tenofovir disoproxil tenofovir and alafenamide and a second additiosal therapeutic agent selected from the group consisting of Irs a particular a compound disclosed herein is combined with a first therapeutic agent selected from the group consisting tenofovir disoproxil tenofovir and alafenamide and a second additional therapeutic wherein the second additional therapeutic agent is a particular a compound disclosed herein is combined with four or more additional therapeutic agents selected from abacavir sulfate raltegravir disoproxil fumarate enfuvirtide abacavir sulfate adefovir disoproxil fumarate rilpivirine disoproxil fumarate atazanavir sulfate atazanavir disoproxil fumarate ritonavir lfate nelfmavir indinavir tenofovir saquinavir lamivudine tenofovir disoproxil efavirenz lamivudine tenofovir disoproxil fumarate lamivudine nevirapine abacavir tenofovir tenofovir disoproxil darunavir atazanavir sulfate atazanavir tenoibvir alafenamide and tenofovir hem a particular a compound disclosed herein abacavir tenofovir tenofovir disoproxil tenofovir disoproxil tenofovir aiafenamide or tenofovir aiafenamide a particular a compound disclosed herein combined with tenofovir tenofovir disoproxil tenofovir or tenofovir aiafenamide a particular a disclosed herein is combined with a first additional therapeutic agent selected from the group consisting abacavir tenofovir tenofovir disoproxil tenofovir and tenofovir aiafenamide and a second additional therapeutic agent selected from the group of and In particular disclosed herein Is combined a additional therapeutic agent selected from the group consisting tenofovir tenofovir disoproxil tenofovir tenofovir aiafenamide hemifnmarate and a second additional therapeutic wherein the second additional therapeutic is In certain a compound disclosed herein is combined with mg tenofovir aiafenamide tenofovir aiafenamide or tenofovir aiafenamide and 200 mg certain a compound disclosed herein is combined with or mg tenofovir aiafenamide tenofovir aiafenamide hemi or tenofovir and 200 mg In certain a compound disclosed herein combined with 10 mg tenofovir aiafenamide tenofovir aiafenamide or tenofovir aiafenamide and 200 mg certain a compound disclosed herein is combined with 25 mg tenofovir aiafenamide tenofovir aiafenamide or tenofovir aiafenamide and 200 mg A compound as disclosed herein a compound of Formulas may be combined with the agents provided herein in any dosage am ount of the compound from 50 mg to 500 of the same as if each combination of dosages were specifically and individually In certain a compound disclosed is combined with tenofovir tenofovir or tenol vir disoproxii hemifurnarate mg In certain a compound disclosed herein is combined or 400 mg tenofovir tenofovir disoproxii or tenofovir disoproxil hemifurnarate and 200 In certain a compound disclosed herein combined with 300 mg tenofovir disoproxii tenofovir disoproxii or tenofovir disoproxii and 200 mg A compound as disclosed herein a compound of Formulas may be with the agents provided herein any dosage amount of the compound from 50 to 500 mg of the same as if each combination of dosages were specifically and individually certain a compound disclosed herein is combined with one or more additional therapeutic agents as described the components of the composition are administered as a simultaneous or sequential When administered the combination may be administered in two or more In certain a compound disclosed herein is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a for example as a solid dosage form for oral In certain a compound disclosed herein is administered one or more additional therapeutic of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic such that therapeutically effective amounts of the compound disclosed herein and or more additional therapeutic agents are both present in the body of the includes administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic for administration of the compound disclosed herein within or hours of the administration of one or more additional therapeutic For in some a unit dose of a compound disclosed herein is administered followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic other a dose of one or therapeutic agents is followed fay administration of a unit dose a compound disclosed herein within seconds or In some a dose of a compound disclosed herein is administered after a period of hours administration of a dose of one or more additional therapeutic In other a unit dose of or more additional therapeutic agents is administered after a period of by administration of a unit dose of a compound XRPD Data In certain the crystalline forms are characterized by the plane intervals determined by an powder diffraction pattern The of XR PD is typically represented by a diagram plotting the intensity of the peaks versus the location of the diffraction angle 20 in The intensities are often in parenthesis with the following very strong medium weak and very weak The characteristic peaks of a given XRPD can be selected according to the peak locations and their relative intensity to conveniently distinguish crystalline structure from Those skilled in the art recognize that measurements of the XRPD locations intensity for a given crystalline form of the same compound will vary within a margin of values of degree 2Θ allow appropriate error tha error margins are represented by For the degree 20 of about denotes a range from about about to about Depending on the sample preparation the calibration techniques applied to the operational and those skilled in the art recognize that the appropriate error of margins for a XRPD can be or In certain embodiments of the the XRPD margin of error is Additional details of the methods and equipment used for the XRPD analysis are described in the The XRPD peaks for the crystalline forms of Form below in Table Table XRPD peaks for crystalline of Formula Form I The XRPD peaks for the form of Form II below in Table Table XRPD peaks for crystalline of Formula I Form II The XRPD peaks for the crystalline form of Farm is below in Table Table XRPD peaks for crystalline forms of Formula I Form The XRPD peaks for the crystalline form of Form IV is below Table XRPD peaks for crystalline forms of Formula I Form IV The XRPD peaks for the crystalline form of sodium is below in Table Table XRPD peaks for forms of Formula Form 1 The XRPD peaks for the crystalline form of oxalic acid crystal Form I is below in Table Table XRPD peaks for crystalline forms of Formula ϊ Oxalic Acid Form I Preparation of the Formula One method of synthesizing I a compound of Formula has been previously described PCX Publication This reference is hereby incorporated herein by in its and specifically with respect to the synthesis of For in one provided is a method of producing a composition comprising one or more polymorphs of A wherein the method comprises combining a compoimd of Formula with a suitable solvent or a mixture of suitable solvents to produce a composition comprising or more polymorphs of compound of Formula In another provided is another method of producing composition comprising one or more polymorphs of i octahyd wherein the comprises with a suitable solvent or a mixture of suitable The choice of a particular solvent or combination of solvents affects the formation favoring one polymorphic form of over suitable for polymorph formation for methyl and any mixtures In another is also one or more polymorphs of produced according to any of the methods described It should be understood the for preparing the polymorphs described herein any one or more of polymorphic Forms I to may yield quantity and quality differences compared to the methods for preparing produced on laboratory Formula and II In one provided is a method of producing a composition comprising polymorphic Form or a mixture of wherein the method comprises combining with a to produce a composition comprising polymorphic Form or a mixture of the wherein the solvent is isopropyl Provided is a polymorphic Form or a mixture of produced by combining with a wherein the solvent is isopropyl Formula Form III one provided is a method of producing a composition comprising polymorphic Form III of wherein the method comprises combining with a solvent to produce a composition comprising polymorphic Form HI of the wherein the solvent is methyl Provided is a polymorphic Form III of arboxamide produced by combining with a solvent wherein the solvent is methyl isobutyl Formula Forms and VIII In one provided is a method of producing a composition comprising polymorphic Form Form and Form or a mixture of wherein method comprises combining carboxamide with a solvent to produce composition comprising polymorphic Form Form and Form or a mixture of the wherein the solvent is methanol Provided is a Form Form and Form or a mixture of I produced by i with a wherein the solvent is Formula Form V In one provided is a method of producing a comprising polymorphic Form V of 1 wherein the method comprises combining 1 with a solvent to produce a composition comprising polymorphic Form V of the i the solvent is Provided is a polymorphic Form V of 1 1 produced by combining with a wherein the solvent is Formula VI In one provided is a method of producing a composition comprising polymorphic Form VI wherein the comprises combining a solvent to produce a composition comprising polymorphic Form of the f ydroxy wherein the solvent is selected from the group consisting of and any mixtures In an the solvent is a mixture of water and Provided is a polymorphic Form VI of a by 1 with a wherein the solvent is selected from the group consisting of aad any mixtures Irs an the is a mixture of water methanol Formula II One method of synthesizing a compound of Formula has been previously described in Publication This reference hereby incorporated herein by reference in its and specifically with respect to the synthesis of method of synthesizing sodium 5 a compound of Formula is described For in one provided is a method of a composition comprising one or more polymorphs of sodium 2 wherein method comprises a compound of Formula with a suitable solvent or a of suitable solvents to produce a composition comprising or more polymorphs of the compound of Formula provided is another method of producing a composition comprising one or more polymorphs of sodium wherein the method comprises combining sodium 1 olate with a suitable solvent or a mixture of suitable The choice of a particular solvent or combination of affects the formation favoring polymorphic of sodium trill 13 over Solvents suitable for polymorph formation may for isopropyl methyl and any mixtures In provided is also one or more polymorphs of sodium produced according to any of the methods described It should be understood that the methods for preparing the polymorphs described herein any polymorphic Form may yield quantity quality differences compared to the methods for preparing sodium produced on laboratory Formula Form I In one provided is a method of producing a composition comprising polymorphic Form of sodium wherein the method comprises combining a sodium base sodium in a solvent to produce a composition comprising polymorphic Form I of sodium wherein the solvent is selected from group of and any mixture In embodiment the is a mixture of ethanol and Provided is also polymorphi Form 1 of sodium S prepared by combining with a sodium base sodium in a wherein the solvent is selected from the group consisting of and any mixture ϊη an embodiment the solvent is a mixture of ethanol and Formula III One method of 1 i a of Formula has been previously described in Publication This reference is hereby incorporated herein reference in its and specifically with respect to the synthesis of One method of potassium a compound of Formula is described For in provided is a method of producing a composition comprising one or more polymorphs of potassium wherem the method comprises combining a of Formula with a suitable or a of suitable to produce a composition comprising one or more polymorphs of the compound of Formula In another aspect provided is another of producing a composition comprising one or more polymorphs of potassium tri fluoroberszy wherein the comprises combining potassium te with a suitable solvent or a mixture of suitable The choice of a particular solvent or combination of solvents affects the formation favoring one polymorphic form of potassium over Solvents suitable for polymorph may for methyl and any In another is one or more polymorphs of potassium l produced according to any of the methods described It should be understood that the methods for preparing the polymorphs described herein any one or more of polymorphic Forms may yield quantity and quality differences compared to the methods for preparing potassium produced on laboratory Formula III Form Is one provided a method of producing a composition comprising polymorphic Form Ϊ of potassium wherein the comprises combining with a base potassium in a solvent to produce a tion comprising polymorphic Form I of potassium 3a wherein the is selected the group consisting of and any mixtures thereof In an the solvent is a mixture of and Provided is also polymorphic Form I of potassium prepared by combining with a potassium base potassium in a wherein the solvent is selected from the group consisting of and any mixtures Formula Form II one provided is a method of producing a comprising polymorphic Form ΙΪ of potassium 3a wherein the method comprises combining a potassium base potassium a solvent to produce a composition comprising polymorphic Form II of potassium wherein the solvent is selected from the group consisting of and any mixtures an the solvent a mixture of acetonitriie and Provided is polymorphic Form II of potassium methan prepared by 1 with a base potassium in a wherein the solvent is selected from the group consisting of and mixtures Formula Form III In one provided is a method of producing a composition comprising polymorphic III of potassium methanop 1 1 wherein the method comprises combining i Tazino with a potassium base potassium in a solvent to produce a comprising polymorphic Form II of potassium wherein the solvent is Provided is also polymorphic Form III of potassium 1 prepared by combining 1 with a potassium base potassium in a wherein the solvent is Formula I In ided is method of producing a composition ciiric acid acid oxalic acid or a of 1 r wherein the method comprises combining with an acid citric fumaric or oxalic in a solvent to produce a composition comprising polymorphic citric acid acid oxalic acid or a mixture of the wherein the solvent is Provided is a polymorphic citric acid fumaric acid oxalic acid or a produced by combining i with an acid eitxic fumaric or oxalic in a wherem the solvent is Uses in Manufacturing Product Formula 1 Provided are also a use of the polymorphs described herein in the manufacture of a drag product The one or more of the polymorphic forms described herein one or more of polym orphic Forms and may be used as an intermediate in the manufacturing process to produce the drug certain Forms I to VIII of methanop are used in the manufacture of an active pharmaceutical fa certain Form Ϊ of is used in the manufacture of an active pharmaceutical In certain II of 1 used in the of an active pharmaceutical certain III of is used in the of an active pharmaceutical fa certain Form of is used in the of active pharmaceutical fa certain Form V of is used in the manufacture of an active In Form VI of is used the manufacture of an active pharmaceutical In Form VII of is in mannfacture of an active In certain Form VIII of 1 used in the manufacture of active pharmaceutical Formula II Provided are also a use of the polymorphs described herein in the manufacture of a drug The one or more of the polymorphic forms described herein polymorphic Form may be used as an intermediate in fee manufacturing process to produce the drug In certain Form I of sodium 1 arc used the manufacture of an active pharmaceutical Formula III Provided are also a use of the polymorphs described herein in the manufacture of a drug The or more of the polymorphic forms described herein one or more of polymorphic Forms and may be used as an intermediate in the manufacturing process to produce the drug In of potassium b are used in the manufacture of an active pharmaceutical In certain Form I of potassium rifl is used in the manufacture of active pharmaceutical In certain Form II of potassium is used in the manufacture of an active pharmaceutical In certain Form III of potassium l is used in the manufacture of an active pharmaceutical Articles of and ts Compositions comprising one or more of fee polymorphic forms described herein one or more of polymorphic Forms I to VIII of 1 polymorphic Form I of sodium and polymorphic Forms II and III of potassium tri fluorobenzy 3 and formulated one or more pharmaceutically acceptable excipients or other ingredients be placed an appropriate arid labeled for treatment of an indicated Accordingly there also is contemplated an article of such as a container comprising a dosage form of one or more of the polymorphic forms described herein one or more of polymorphic Forms I to VIE of polymorphic I of sodium and polymorphic Forms and III of and a label containing instructions for use of the In some the article of is a container comprising a dosage of one or more of the polymorphic forms described herein one or more of polymorphic I to VIII of polymorphic Form 1 of sodium and polymorphic Forms and III of potassium one or more pharmaceutically acceptable excipients or other In one embodiment of the articles of manufacture described the dosage form is a Kits are For a kit can comprise a dosage form of a pharmaceutical and a package containing instructions for use of the composition in treatment of a medical The instructions for use in the kit may be for treating In certain the instructions for use in the kit may be for treating In certain the and solvate forms described herein may potentially exhibit For in certain the solvate forms herein may potentially exhibit improved Such improved stability could have potentially beneficial impact on the manufacture of the Compound of Formulas such as for example the ability to store process intermediate for extended periods of Improved stability could also potentially benefit a composition or pharmaceutical composition of the Compound of Formulas certain the solvate forms described may also result in improved yield of the of Formulas or potentially result in an improvement of the quality of the Compound of Formulas certain the salt and solvate forms described herein may also exhibit pharmacokinetic properties potentially improved Methods Formula 1 Form was added to a glass Isoproparsol was the vial was and the suspension was stirred at about 21 for not less than 5 Formula I Form I was isolated as a solid from the suspension by characterized as discussed Formula I Form II was added to a glass Methyl ether was the was and the suspension was stirred at about 21 for not less than 5 I Form 11 was isolated as a solid from the suspension by and characterized as discussed octa 1 1 was in aw for 5 days with Formula 1 Form II was isolated as a solid from the suspension by and characterized as discussed Formula I HI from Compound Compound A solution of about Compound g methylene chloride was concentrated to a residue under 7 followed by was added to the resulting The method of preparing compound can be determined by one skilled the for as described Serial filed December COMPOUNDS AND THEIR PHARMACEUTIC The mixture was heated to an internal temperature of approximately 75 After the reaction was cooled to approximately 20 and hydrochloric acid was and the resulting stirred for 5 The phases were and the organic was washed with aqueous sodium chloride solution followed by This solution was while gradually adding 3 volumes of ssopropyl alcohol bath torr The resulting slurry was slowly cooled to The product was filtered and and Formula I Form III was characterized as discussed Formula I Form 111 from Formula I 1 i were added to a reaction vessel and seeded with Formula I Form The slurry was allowed to age at room temperature for about Formula I Form III was isolated as a solid from the suspension by and characterized as discussed Formula I Form IV 1 and potassium acetate were added to a glass Methanol was the vial and the suspension was stirred at about After days the solids were isolated from fee suspension by and the filtrate Afler slow evaporation over 16 large crystals of Formula I Form IV were found in the filtrate Formula I Form carboxamide was mixed with grams of water at room forming a After several crystals suitable for crystal crystallography were found Formula Form VI mg of carboxamide was suspended in 2 mL of rae solution The suspension was filtered the next day and several days after crystals suitable for single crystal were found in the filtrate and Formula I Form VII carboxamide suspended in grams of methanol at room A sample of the suspension was filtered for testing after several and several days solids suitable for single crystal crystallography were found in the filtrate and Formula I Form VIII 53 g suspended SO of methanol room To the mixture was slowly added grams of dissolved in 20 mL Full addition of KOH solution resulted a A suspension formed over the course of two days and a sample was filtered for testing after ten After several solids suitable for single crystal crystallography were found the filtrate and Formula II Form I 1 ethanol were added to a reaction vessel warmed to about 75 Aqueous sodium hydroxide mL 2 M was added over approximately 30 after which the slurry was cooled to approximately 20 over approximately one Sodium Form I was collected by washed with and dried MR I I J J I Ϊ Formula I Citric Acid Form I 1 and citric acid were added to a glass vial was the vial was and the mixture was stirred at about for two The vial was vented and the solvent was allowed to evaporate at about After eight weeks at room crystals were found in the vessel and as a Formula I citric Formula Acid Form 1 acid were added to a glass Te was the and the suspension stirred about for two An additional 1 mL of tetrahydrofuran was and the mixture was heated to 45 After about hours at 45 ftC the mixture was fou d to be fully dissolved wd was removed from the heat The vial was and the solvent to evaporate at room After one day solids were observed the and it was After eight weeks large crystals found in the capped vial and identified as a 1 Formula I acid Formula I Oxalic Acid Form oxalic acid were added to a glass Tetrahydrofuran was the vial and the resulting solution was stirred at about for about two The vessel was and the solvent was allowed to evaporate at room After day solids were observed the vial and it was Two days later large crystals were in the vial and were identified as a 1 Formula I oxalic acid Formula Form I 406 carboxamsde was combined with 200 mg potassium acetate 5 mL of methanol at room in a A sample of the suspension was filtered the next day for After several solids suitable for single crystal crystallography were found In the filtrate and was charged to a reaction flask and followed by The mixture was stirred at room temperature resulting in a In a separate vessel potassium hydroxide was deionized water The potassium hydroxide solution was transferred syringe to the stirring suspension over about hours followed by rinse into the reactor with water after the base solution transfer was A sample of about mL of the resulting suspension was The filtrate was retained and stored at room After several weeks it had evaporated the vessel contained large which were Identified by single as Formula III Form Formula III Form II mg of was suspended mL of After one week a sample was filtered for After several solids suitable single crystal crystallography were in the filtrate and Formula 111 Form III A 4 mL glass vial was charged 140 mg of and 73 mg of potassium phosphate and 2 of The vial was capped and placed in a rotating mixer to provide gentle and constant The experiment was carried out at room More than a week later and more than a month later solids were isolated by and examined by Large crystals suitable for Single Crystallography were found and The crystalline forms of the present were characterized by various analytical including powder diffraction differential scanning thermogravimetric analysis and dynamic vapor sorption using the procedures described Powder XRPD analysis was conducted on a using copper radiation λ Samples were prepared for analysis by depositing the powdered sample in the center of an aluminum holder equipped with a zero background The generator was operated at a voltage of 45 kV and amperage of 40 Slits used were Sailer antiscatter and The sample rotation speed was 2 Scans were performed 2 to 20 during min with a step size of Data analysis was performed by Highscore version and data viewer version The XRPD pattern for Form I is represented in Figure I The XRPD pattern for II is represented in Figure The XRPD pattern for Form III is represented in Figure The XRPD pattern for 1 Form IV is represented Figure The XRPD pattern for sodium 3a 1 1 1 Form 1 represented in Figure The calculated XRPD pattern for sodium Form Ϊ represented in Figure was calculated by using Mercury Development Single data for sodium I was input into Mercury Development to calculate the XRPD pattern for sodium Bulk such as arity between the temperature was obtained on a Miniflex II XRD power settings of scan speed of degrees per a Miniflex goniometer an a scan of to an incident slit of a length limiting slit of and a receiving slit of continuous scan a receiving slit of The sample was prepared by smoothing about 20 mg of solids on a silicon disk mounted in a metal Acquisition temperature was The XRPD pattern for sodium J Form I is further represented in Figure The calculated XRPD pattern for sodium d For ί represented in Figure was calculated by using Mercury Single crystal data for sodium 1 Form I was input into Mercury Development to calculate the XRPD pattern for sodium 1 Form Bulk such as stoichiometry arity between the temperature was obtained on a Rigaku XRD using power settings of speed of degrees per a Miniflex goniometer and an scan range of to an incident slit of a length limiting slit of and receiving slit of continuous scan and a receiving of The was prepared by smoothing about 20 rag of solids on a silicon disk mounted a metal Acquisition temperature was Figure 16 compares the calculated XRPD pattern of sodium Form I to the experimental XRPD pattern of sodium Form The comparison shows the degree to which the calculated XRPD and experimental XRPD Strong agreement indicates the solved crystal structure is also the crystal stmciure of the material analyzed directly by determination can support orthogonal data about the composition of the such as The actual and calculated XRPD pattern for 1 i oxalic acid crystal Form Ϊ is represented in Figure Differential scanning Thermal properties were evaluated using a Differential Scanning Calorimetry instrument TA New Approximately 1 to of solid sample was placed in a standard pan vented with a pinhole for each experiment and heated at a rate of 5 to under a 50 nitrogen Data analysis was conducted using Universal Analysis 2000 Version New Heat of fusion analysis was conducted by integration of the ic melting The DSC for Form I is represented in Figure The DSC for carboxarnide Form is represented in Figure The DSC for sodium Form I is represented Figure analysis was on a TGA instrument TA New Approximately 1 to mg of solid sample was placed in an open pan for each experiment and heated at a rate of 5 to 10 under a 60 nitrogen purge Data analysis was conducted using Universal Analysis 2000 Version New The TGA for 1 carboxamide Form I is represented Figure The TGA for carboxasnide Form ΠΪ is represented in Figure The TGA for sodium 1 Form is represented Figure Dynamic vapor The was evaluated at room temperature using a dynamic vapor sorption instrument TA New Water adsorption and desorption were studied as a function of relative humidity over the range of 0 to 25 The relative humidity in the chamber was increased by RH and held until the so lid and atmosphere reached The test was continued until passed or expired after 5 or At this RH was raised higher and the process was repeated until RH was reached and During this the water sorption was For the relative humidity was decreased a similar manner to measure a The cycle was optionally All experiments were operated in variation over to determine equilibration Approximately g of solid was Data analysis was using Universal Analysis 2000 Version New The DVS for carboxamide Form I is represented in Figure The DVS for carboxamide Form TIT is represented Figure The DVS for sodium Form I is represented in Figure The single crystal studies were carried out on a Broker APEX II Ultra equipped with Mo radiation Crystals of the subject compound were cut into a x x section and on a with Data were collected in a nitrogen gas stream at a particular as shown in the Tables below K A total number of reflections were collected covering the Gs Certain reflections were to be symmetry independent with Indexing and refinement indicated a crystal system or The space which was uniquely defined by the systematic absences in the was found Pi and The data were integrated using the Broker SAINT software program and scaled using the software Solution by direct methods produced complete phasing model compatible with the proposed All nonhydrogen atoms were refined by All hydrogen atoms were placed using a riding Their positions were constrained relative to their parent atom using the appropriate command in data are summarized in tables The absolute stereochemistry was set to conform to previously studied samples of the same The single crystal crystallography data for Formula I Forms are in Table 2A The single crystal crystallography data for Formula I Forms are summarized in Table The indexing data for Formula II Form is summarized in Table 2C The single crystal crystallography data for the crystals of the in vention summarized in Table 2C The single crystal crystallography data for Formula III Forms I is summarized in Table Data from furt her characterization of the crystals summarized in Tables 3 A and Data from further characterization of the crystals are also summarized in Tables and Table 2 Single Crystal Data for Formula I Forms I IV and II Form I Table Single Crystal Data for Formula I Forms V VIII Table 2 Data for Formula II Form I The crystal crystallography data for Formula Form I is Table Table 2I Single Crystal Data for Form I Acquisition Space Z Unit Call Dimensions C42 F6 N6 Group Na2 P2I2121 4 Distance Angle Form and Solvent in Solvent a b C a identification lattice β y Formula none 90 90 90 I Table Single Data for I Single Crystal Data for Fonnuk Forms Table Crystal Data and Structure Refinement for Formula I Table Crystal Data and Structure Refinement for Formula Ϊ Forms V Table Crystal and Structure Refinement for Formula I Table Crystal Data Structure Refinement for Form Formula HI Form II Formula Form III certain of the Formula III is In certain Formula III is hydrated with five to six water Each of references including all patent applications and publications cited in the present application is incorporated herein by reference in its as if each of them is individually it would be appreciated in the above teaching of the skilled in the ar could make certain or modifications to the and these equivalents would still be wi thin the scope of the invention defined by the appended claims of the Each of the references including all patent applications and publications cited in the present application is incorporated herein by reference in its as if each of them is it would be appreciated in the above teaching of the skilled in the art could make certain changes or modifications to the and these equivalents would still be within the scope of the invention defined by the appended claims of the insufficientOCRQuality